Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects

The use of TLR agonists as an anti-cancer treatment is gaining momentum given their capacity to activate various host cellular responses through the secretion of inflammatory cytokines and type-I interferons. It is now also recognized that the perioperative period is a window of opportunity for vari...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Matzner, Pini, Sorski, Liat, Shaashua, Lee, Elbaz, Ely, Lavon, Hagar, Melamed, Rivka, Rosenne, Ella, Gotlieb, Neta, Benbenishty, Amit, Reed, Steve G., Ben-Eliyahu, Shamgar
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4724303/
https://ncbi.nlm.nih.gov/pubmed/26453448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29885
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados